Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 21 02:11PM ET
37.64
Dollar change
-0.86
Percentage change
-2.23
%
IndexRUT P/E- EPS (ttm)-2.64 Insider Own2.89% Shs Outstand54.69M Perf Week6.72%
Market Cap2.06B Forward P/E- EPS next Y-3.10 Insider Trans0.00% Shs Float53.11M Perf Month-5.81%
Income-124.61M PEG- EPS next Q-0.74 Inst Own110.73% Short Float12.64% Perf Quarter29.39%
Sales4.37M P/S471.06 EPS this Y-17.19% Inst Trans2.09% Short Ratio10.11 Perf Half Y23.13%
Book/sh5.22 P/B7.21 EPS next Y-10.27% ROA-38.37% Short Interest6.71M Perf Year-12.51%
Cash/sh4.28 P/C8.79 EPS next 5Y- ROE-42.09% 52W Range22.11 - 47.91 Perf YTD-5.09%
Dividend Est.- P/FCF- EPS past 5Y26.01% ROI-50.24% 52W High-21.44% Beta1.46
Dividend TTM- Quick Ratio8.84 Sales past 5Y-10.39% Gross Margin33.06% 52W Low70.24% ATR (14)1.60
Dividend Ex-Date- Current Ratio8.84 EPS Y/Y TTM-16.48% Oper. Margin-3088.20% RSI (14)51.38 Volatility4.14% 3.91%
Employees148 Debt/Eq0.01 Sales Y/Y TTM304.92% Profit Margin-2854.75% Recom1.25 Target Price63.29
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-41.81% Payout- Rel Volume0.42 Prev Close38.50
Sales Surprise160.07% EPS Surprise-19.12% Sales Q/Q272.73% EarningsNov 02 AMC Avg Volume663.60K Price37.64
SMA201.87% SMA50-0.25% SMA20015.94% Trades Volume203,142 Change-2.23%
Date Action Analyst Rating Change Price Target Change
Dec-20-23Initiated TD Cowen Outperform
Nov-10-23Upgrade Wells Fargo Underweight → Equal Weight $27
Aug-22-23Initiated Wells Fargo Underweight $21
Sep-17-21Initiated Jefferies Buy $66
Sep-10-21Initiated SVB Leerink Outperform $68
Jul-22-21Initiated Guggenheim Buy $66
Feb-21-20Initiated Cantor Fitzgerald Overweight $8
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Feb-20-24 08:26AM
Feb-06-24 04:01PM
Feb-05-24 08:01AM
Nov-27-23 04:15PM
Nov-17-23 01:08PM
11:15PM Loading…
Nov-07-23 11:15PM
04:01PM
Nov-06-23 06:47PM
04:01PM
12:15PM
07:00AM
06:30AM
Nov-05-23 03:00PM
Nov-04-23 05:39AM
Nov-02-23 04:25PM
04:01PM Loading…
04:01PM
Sep-26-23 07:01AM
Sep-25-23 08:31AM
Aug-22-23 09:35AM
Aug-08-23 05:30PM
04:21PM
04:01PM
Jul-11-23 08:01AM
Jul-06-23 08:01AM
Jun-10-23 10:45AM
Jun-08-23 04:01PM
Jun-02-23 08:01AM
May-31-23 08:01AM
May-23-23 06:10AM
May-15-23 08:01AM
06:05PM Loading…
May-04-23 06:05PM
05:03PM
04:01PM
Apr-18-23 05:58AM
Apr-12-23 08:13AM
Mar-29-23 09:01AM
Mar-02-23 05:40AM
Feb-28-23 04:01PM
Feb-27-23 10:25AM
Feb-26-23 09:00AM
Feb-16-23 04:01PM
Feb-15-23 07:00AM
Feb-03-23 07:01AM
Jan-18-23 02:38PM
Dec-06-22 06:00AM
Dec-02-22 09:31AM
Nov-27-22 09:45AM
Nov-10-22 04:01PM
Nov-09-22 05:25PM
04:01PM
Nov-02-22 10:01AM
Nov-01-22 10:01AM
Aug-08-22 05:25PM
04:01PM
Jul-21-22 08:00AM
Jul-08-22 09:26AM
Jul-06-22 09:55AM
07:20AM
Jul-05-22 03:57PM
Jul-04-22 11:49AM
Jul-01-22 04:11PM
10:11AM
Jun-30-22 06:01PM
Jun-22-22 09:24AM
Jun-21-22 08:00AM
Jun-20-22 10:35AM
Jun-16-22 04:01PM
Jun-06-22 04:05PM
May-19-22 09:23AM
May-11-22 08:13AM
May-06-22 08:10AM
May-05-22 05:55PM
04:01PM
May-04-22 08:25AM
Feb-28-22 04:01PM
Feb-22-22 04:01PM
Feb-17-22 03:07AM
Feb-13-22 07:47AM
Feb-10-22 04:05PM
Feb-02-22 01:38PM
Jan-10-22 08:40AM
Dec-15-21 04:57AM
01:38AM
Dec-11-21 06:53PM
Dec-08-21 08:01AM
Nov-12-21 07:00AM
Nov-11-21 07:01AM
Nov-09-21 06:15PM
04:01PM
Oct-28-21 03:05PM
Oct-25-21 11:51AM
Sep-29-21 08:13AM
12:00AM
Sep-24-21 07:01AM
Sep-23-21 08:01AM
Sep-16-21 07:01AM
Sep-14-21 10:31AM
Sep-13-21 09:01AM
Aug-25-21 03:55PM
Aug-05-21 06:05PM
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jimenez Freddy A.SVP & GENERAL COUNSELFeb 13Option Exercise3.8624,16693,16325,924Feb 15 04:05 PM
Martin Samuel BatesSVP AND CFOJan 02Option Exercise2.7810,75029,88535,128Jan 04 04:05 PM